Modified vaccinia ankara
- Generic Name
- Modified vaccinia ankara
- Brand Names
- Jynneos
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- TU8J357395
- Background
Modified Vaccinia Ankara (MVA) refers to an attenuated strain of the Vaccinia virus. Vaccines using MVA are live and non-replicating, and are produced using Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN).
- Indication
Modified vaccinia ankara is a vaccine indicated for the prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection. In the EU, it is additionally indicated for the prevention of other diseases caused by the vaccinia virus.
- Associated Conditions
- Ebola Virus Disease, Monkeypox, Variola Major (Smallpox)
- Associated Therapies
- -
A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Target Recruit Count
- 450
- Registration Number
- NCT05740982
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Kaiser Permanente Washington Health Research Institute, Seattle, Washington, United States
🇺🇸Duke Vaccine and Trials Unit, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.